
Antibe Therapeutics Inc
TSX:ATE

Operating Margin
Antibe Therapeutics Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
Country | Company | Market Cap |
Operating Margin |
||
---|---|---|---|---|---|
CA |
![]() |
Antibe Therapeutics Inc
TSX:ATE
|
4.7m CAD | N/A | |
US |
![]() |
Eli Lilly and Co
NYSE:LLY
|
660.9B USD |
42%
|
|
UK |
![]() |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
3%
|
|
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
424.9B USD |
26%
|
|
CH |
![]() |
Roche Holding AG
SIX:ROG
|
203.1B CHF |
33%
|
|
UK |
![]() |
AstraZeneca PLC
LSE:AZN
|
182B GBP |
24%
|
|
DK |
![]() |
Novo Nordisk A/S
CSE:NOVO B
|
1.5T DKK |
46%
|
|
CH |
![]() |
Novartis AG
SIX:NOVN
|
194.2B CHF |
33%
|
|
US |
![]() |
Merck & Co Inc
NYSE:MRK
|
211.9B USD |
38%
|
|
IE |
E
|
Endo International PLC
LSE:0Y5F
|
183.4B USD |
11%
|
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
143B USD |
29%
|
Antibe Therapeutics Inc
Glance View
Antibe Therapeutics, Inc. is a biotechnology company, which engages in the development of medicines for pain and inflammation. The company is headquartered in Toronto, Ontario and currently employs 37 full-time employees. The company went IPO on 2013-06-18. The firm is focused on pain, inflammation, and regenerative medicine. The Company’s products pipeline includes Otenaproxesul, ATB-352, and ATB-340. Otenaproxesul is a novel anti-inflammatory drug that releases hydrogen sulfide and combines hydrogen sulfide with naproxen, non-steroidal, anti-inflammatory drug. ATB-352 is a hydrogen sulfide-releasing derivative of ketoprofen. ATB-340 is a gastrointestinal-safe version of low-dose aspirin for cardiovascular and cancer protection. The Company, through its wholly owned subsidiary, Citagenix Inc. (Citagenix) is a seller of tissue regenerative products servicing the orthopaedic and dental marketplaces. Citagenix’s portfolio consists of branded biologics and medical devices that promote bone regeneration.

See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Antibe Therapeutics Inc's most recent financial statements, the company has Operating Margin of 0%.